PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
News|Articles|June 10, 2022
EMA Adopts List of Critical COVID-19 Medicines
Author(s)Pharmaceutical Technology Editors
The agency’s Medicines Shortages Steering Group has adopted a list of critical COVID-19 vaccines and treatments so they may be monitored for potential shortages.
Advertisement
The European Medicines Agency (EMA) announced on June 8, 2022 that its Medicines Shortages Steering Group has created a list of critical authorized COVID-19 vaccines and treatments in order to monitor them for potential shortages. The list, which will be updated if changes in the pandemic situation occur, was created in consultation with the Medicines Shortages Single Point of Contact Working Party, the Emergency Task Force, and EMA’s Patients' and Consumers' Working Party and Healthcare Professionals' Working Party.
Companies that hold marketing authorizations of these medicines are required to update the agency with data on potential or actual shortages and available stock. Reports on estimated demand will also be provided by European Union Member States, enabling the agency to coordinate with the European Commission and EU Member States to prevent shortages of these critical medicines. EMA will work with authorization holders and national competent authorities to gather information about the medicines on the list.
Source:
Advertisement
Related to this article
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
Karthik Iyer, Eli Lilly, details an AI system linking GMP findings, audits, and deviations for cited, inspection-ready regulatory intelligence.
At the PDA/FDA Joint Regulatory Conference 2026, Helen Motamen, MS
global head, Sanofi Quality Audit, Inspection, Intelligence & Advocacy, at Sanofi, provided advice for creating a strong internal audit program.
At PDA/FDA Joint Regulatory Conference 2026, PCI Pharma's Bassler details how a QMS overhaul turned an FDA 483 into stronger quality culture.
AI can turn medical device risk management into a continuous signal.
On PharmTech.com this week, coverage of upcoming events continued, experts continued to discuss the use of AI in pharma, and validation in oral solid dosage product production was emphasized.
This article explores the historical use of silicone oil in the performance of primary drug product packaging; design of experiment test results for selection of the cleaning agent and CCPs; assessment of visible residue limits and Fourier-transform infrared spectroscopy surface analysis; and setting health-based exposure limits for silicone oil using a non-uniform distribution model, and a previously published permitted daily exposure.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Driving Quality Culture to Manage Risk: Lessons from an FDA Inspection Response
2
FDA's IND Pilot Puts CMC Review First
3
Mature Medicines Divestment Signals Shift in Manufacturing Strategy
4
Spray Drying Capacity Signals Faster Paths for Poorly Soluble Drugs
5